Cardiogen

What is it?

Cardiogen is a Khavinson bioregulator peptide targeting cardiomyocytes — claimed, like the rest of the family, to modulate gene expression for cardiac contractility and tissue maintenance. It’s part of the vascular/cardiovascular corner of the Khavinson short-peptide bioregulator family, alongside Vesugen.

What does it do in my body?

Like the rest of the Khavinson family, Cardiogen’s claimed mechanism is that a short tissue-derived peptide crosses cell and nuclear membranes, binds DNA promoter regions, and modulates transcription in a tissue-specific way — here, in cardiac tissue. There is no Cardiogen-specific mechanism data beyond this general family-level theoretical claim; the family’s underlying nuclear-penetration mechanism has in-vitro support (Fedoreyeva et al. 2011, Biochemistry (Mosc), 22117547), but that work was not done on Cardiogen specifically.

How can it help me?

• Where the science stands: Directory lists “Moderate” (12 studies, 9 human) — but the 9 human studies are a citation-mismatch, not real peptide evidence. Actual base: preclinical/anecdotal

The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.

Is it dangerous? What are the side effects?

No Cardiogen-specific adverse-event data exists. The family-wide reported profile in the Russian literature is mild and uncommon: occasional injection-site reactions, transient mild headache early in a cycle.

The real risk isn’t the molecule — it’s the supply chain. Khavinson-family peptides are the dominant gray-market counterfeit category in the peptide space, and Cardiogen’s thin evidence base makes it an even easier target for mislabeling since there’s little independent literature to check a seller’s claims against. Third-party COA verification matters more here than for almost any other peptide class.

Regulatory status: Cardiogen is research_only in the US — not FDA-approved for human use, sold as a research compound, not eligible for compounding. It is not a controlled substance. Unlike Thymalin, Cardiogen holds no clinical-use approval anywhere.

Part 1 — How to reconstitute it

What you'll need: bacteriostatic water (sterile, preserved water you mix the powder with) and a separate, larger reconstitution syringe just for mixing — not the small syringe you inject with.

The exact bacteriostatic-water volume and resulting concentration for Cardiogen are covered in the dosing notes and the deeper-science view. Confirm the right volume for your vial before mixing.

How to mix it

• Tilt the vial and let the bacteriostatic water run slowly down the inside glass wall — never squirt it straight onto the powder.
• Swirl gently to dissolve. Never shake — shaking can damage the peptide.
• Store the reconstituted vial refrigerated and out of light.
• Use it within the beyond-use window your source specifies — reconstituted peptides are commonly used within a few weeks; confirm the window for your specific peptide.

Use the free reconstitution calculator to turn any vial size + water volume into exact units on an insulin syringe.

Part 2 — Typical dosing

Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.

The syringe. Use a 0.3 mL U-100 insulin syringe — it's sized for these small subcutaneous doses. Inject subcutaneously (into the fat just under the skin) and rotate injection sites.

Educational purposes only — this reflects what the Russian-school protocol convention and the peptide community actually use, stated plainly; it is not medical advice.

There is no Western-validated dosing protocol for Cardiogen, and — unlike some other provisional members — no meaningful clinical or community dosing record either, given the thin evidence base. What exists is only the generic Khavinson-family cycle pattern:

• Cycle structure: a short course — typically 10–20 consecutive days — followed by a long rest, repeated 2–3 times per year, per the broader family convention.
• Dose: synthetic Khavinson short peptides generally converge around ~100–200 mcg/day over the cycle, but no Cardiogen-specific dose-finding data exists to confirm this applies here.
• Storage: lyophilized powder is stable cold; once reconstituted with bacteriostatic water, refrigerate and use within roughly 28 days.

Treat any specific number for Cardiogen as generic family convention, not peptide-specific validated dosing.

Turning milligrams into syringe units. On a U-100 syringe, 100 units = 1 mL, so 1 unit = 0.01 mL. At a concentration of C mg/mL, a dose of D mg = D ÷ C mL = (D ÷ C) × 100 units. Example: at 5 mg/mL, a 0.5 mg dose = 0.1 mL = 10 units. Your exact units depend on your own vial's mg and how much bacteriostatic water you added — use the same concentration you mixed above.

What should I avoid combining — and what's synergistic?

Cardiogen doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.

How can I buy this?